The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
T-cell exhaustion in the tumor microenvironment
Open accessAbstract
T-cell exhaustion was originally identified during chronic infection in mice, and was subsequently observed in humans with cancer. The exhausted T cells in the tumor microenvironment show overexpressed inhibitory receptors, decreased effector cytokine production and cytolytic activity, leading to the failure of cancer elimination. Restoring exhausted T cells represents an inspiring strategy for cancer treatment, which has yielded promising results and become a significant breakthrough in the cancer immunotherapy. In this review, we overview the updated understanding on the exhausted T cells in cancer and their potential regulatory mechanisms and discuss current therapeutic interventions targeting exhausted T cells in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Self-citationMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Cited by
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992
“Interestingly, these T cells also manifested immuno-suppressive phenotypes of exhausted 39,40 or regulatory T cells 41 .”
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
“Systemic Immune Responses Are Required for Tumor Eradication Effective immunotherapy induces marked changes in both the microenvironment and the periphery, but the prevailing dogma holds that productive immunotherapy functions by reinvigorating immune cells that are actively suppressed in the tumor microenvironment (J…”
Immunosenescence: molecular mechanisms and diseases
Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., Cheng, Q., Luo, P., Zhang, Y., & Han, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01451-2 · Cited by 960
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Kroeger, D. R., Milne, K., & Nelson, B. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2762 · Cited by 610
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 480
Pyroptosis: a new paradigm of cell death for fighting against cancer
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., Li, X., Yang, J., Xiang, B., & Yi, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01959-x · Cited by 467
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Sung, Y.-C., Jin, P.-R., Chu, L.-A., Hsu, F.-F., Wang, M.-R., Chang, C.-C., Chiou, S.-J., Qiu, J. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 452
Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
Wu, S. Z., Roden, D. L., Wang, C., Holliday, H., Harvey, K., Cazet, A. S., Murphy, K. J., Pereira, B., Al‐Eryani, G., Bartonicek, N., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104063 · Cited by 436
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“Recent studies have shown that the exhaustion and functional impairment of T cells in the TME is a defining feature of many cancers (Jiang et al., 2015).”
BackgroundBaessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Zhao, Y., Shao, Q., & Peng, G. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0344-8 · Cited by 382
Cancer stem cells: The root of tumor recurrence and metastases
Peitzsch, C., Tyutyunnykova, A., Pantel, K., & Dubrovska, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.011 · Cited by 372
Thymic involution and rising disease incidence with age
Palmer, S., Albergante, L., Blackburn, C. C., & Newman, T. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714478115 · Cited by 364
Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2017) · Nature Communications · doi:10.1038/ncomms14754 · Cited by 350
Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kückelhaus, J., Vollmer, L., Goeldner, J. M., Behringer, S. P., Scherer, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28523-1 · Cited by 343
Becker, W. R., Nevins, S. A., Chen, D. C., Chiu, R., Horning, A. M., Guha, T. K., Laquindanum, R., Mills, M., Chaib, H., Ladabaum, U., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01088-x · Cited by 321
Programmed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 316
Self-citationVari, F., Arpon, D., Keane, C., Hertzberg, M. S., Talaulikar, D., Jain, S., Cui, Q., Han, E., Tobin, J., Bird, R., et al. (2018) · Blood · doi:10.1182/blood-2017-07-796342 · Cited by 313
The Role of PD-1 in Acute and Chronic Infection
Jubel, J. M., Barbati, Z. R., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00487 · Cited by 307
Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment
Kaltenmeier, C., Yazdani, H. O., Morder, K., Geller, D. A., Simmons, R. L., & Tohme, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785222 · Cited by 305
The Biodistribution and Immune Suppressive Effects of Breast Cancer–Derived Exosomes
Wen, S. W., Sceneay, J., Lima, L. G., Wong, C. S. F., Becker, M., Krumeich, S., Lobb, R. J., Castillo, V., Wong, K. N., Ellis, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0868 · Cited by 289
Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., Su, R., Hong, L., Lu, H., Zhang, F., et al. (2019) · Hepatology · doi:10.1002/hep.30593 · Cited by 269
Positive Role of Chinese Herbal Medicine in Cancer Immune Regulation
Wang, S., Long, S., Deng, Z., & Wu, W. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500780 · Cited by 257
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Allison, K. E., Coomber, B. L., & Bridle, B. W. (2017) · Immunology · doi:10.1111/imm.12777 · Cited by 109
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123540 · Cited by 78
Self-citationmiRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy
Zhang, M., Shi, Y., Zhang, Y., Wang, Y., Alotaibi, F., Qiu, L., Wang, H., Peng, S., Liu, Y., Li, Q., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02507-w · Cited by 65
Rong, Y., Dong, Z., Hong, Z., Jin, Y., Zhang, W., Zhang, B., Mao, W., Kong, H., Wang, C., Yang, B., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.009 · Cited by 59
Benchmarking AI Models for In Silico Gene Perturbation of Cells
Li, C., Gao, H., She, Y., Bian, H., Chen, Q., Liu, K., Wei, L., & Zhang, X. (2024) · doi:10.1101/2024.12.20.629581 · Cited by 24
Sekido, K., Tomihara, K., Tachinami, H., Heshiki, W., Sakurai, K., Moniruzzaman, R., Imaue, S., Fujiwara, K., & Noguchi, M. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104462 · Cited by 23
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…marked by reduced proliferation, decreased cytokine production and heightened inhibitory checkpoints which ultimately weaken anti-tumor immunity (Jiang et al. 2015; Neyens et al. 2023; Hetemäki et al. 2025). iKZF2 is upregulated in leukemia and lymphoma, including leukemia stem cells, where it…”
Metadata
- Authors
- Jiang, Y., Li, Y., & Zhu, B.
- Venue
- Cell Death & Disease
- Published
- 2015-06-18
- Volume
- 6
- Issue
- 6
- Pages
- e1792-e1792
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W1540592014
- Cited by
- 1,157
- References
- 108
- FWCI
- 21.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.